Introduction {#sec1-1}
============

The heritability of schizophrenia is estimated to be around 80%, with around 10-fold risk increase in first degree relatives\[[@ref1]\]. It is believed that the genetic predisposition to schizophrenia is related to a number of low-penetrance variants, with these interacting with environmental factors. The current view regarding the pathophysiology of schizophrenia strongly implicates the dysfunction in the dopaminergic neurotransmitter system. The catechol-O-methyl-transferase (*COMT*) gene is one of the most significant candidate genes for schizophrenia, since COMT catalyzes the transfer of the methyl group of S-adenosyl-l methionine (AdoMet) to the catecholamine neurotransmitters, and thus inactivating them. The human gene that encodes COMT is located on the chromosome 22q11\[[@ref2]\]. This region is affected with a microdeletion in the velocardiofacial syndrome, a condition that is frequently associated with schizophrenia. Two co-dominant alleles (G and A) in exon 4 of the *COMT* gene influence the amino acid structure (Val or Met) at codon 158. The COMT enzyme activity is genetically polymorphic with a trimodal distribution (high activity in Val/Val genotype, intermediate activity in Val/Met genotype, and low activity in Met/Met genotype). The difference in COMT activity is three- to four-fold (Val/Val vs. Met/Met).

The results of the studies on the Val158Met polymorphism of the *COMT* gene are conflicting, with a number of studies suggesting a possible effect of the Val158Met polymorphism in vulnerability to schizophrenia\[[@ref3]--[@ref10]\], and others showing no association\[[@ref11]--[@ref18]\].

The aim of this study was to utilise a homogeneous Syrian case-control sample of categorically-defined Schizophrenia to investigate its association with the Val158Met polymorphism of the *COMT* gene.

Subjects and Methods {#sec1-2}
====================

 {#sec2-1}

### Study Cohort {#sec3-1}

The study cohort consisted of 71 unrelated schizophrenic subjects (45 men, 26 women; 37± 10 years) and 102 unrelated healthy controls (62 men, 40 women; 40 ± 10 years). Patients were recruited from the Ibn Khaldoon hospital in Aleppo, Syria. All patients met the DSM-IV diagnosis for schizophrenia. Appropriate ethical and governance permission was obtained from the local authorities prior to blood sample collection. Patients and controls were gender-matched and were all from the same ethnical background.

### Genotype Analysis {#sec3-2}

The Val158Met of the *COMT* gene was genotyped by a new optimized PCR-RFLP method using the restriction enzyme *Nla*III. A 108 bp fragment containing the single nucleotide polymorphism studied was amplified using the PCR method. The PCR reaction was carried out in a total volume of 20μl containing 100-150ng genomic DNA as the template, 0.5 μM of each primer (synthesized by VBC-Biotech, Austria), 2.3mM MgCl2, 200μM of each dNTP, 1X Taq buffer (10 mM Tric-HCl pH 8.4, 50 mM KCl) and 0.75 units of Taq DNA polymerase (Fermentas, Lithuania). PCR amplification was carried out in a MasterCycler® thermal cycler (Eppendorf, Germany) with an initial denaturation step at 94°C for 5 minutes followed by 31 cycles of 94°C for 30 seconds, 62°C for 30 seconds and 72°C for 10 seconds, and a final extension step at 72°C for 5 minutes. The primer sequence for the forward and reverse primers were 5'-CGAGGCTCATCACCATCGAGATC-3' and 5'-CTGACAACGGGTCAGGAATGCA-3', respectively. The PCR product was digested with *Nla*III (FastDigest® *Nla*III enzyme, Fermentas®, Lithuania) according to the manufacturer instructions. The resulting fragments were separated on agarose gels (2.5%). Digestion of the amplified fragment with NlaIII showed 3 bands in heterozygotes (108, 72 and 36 bp). The amplified fragment remained intact in Val homozygotes after digestion with the restriction enzyme, with agarose gel electrophoresis showing a single 108 bp band. In Met homozygotes 2 bands were produced (72 and 36 bp).

Results {#sec1-3}
=======

Genotypes in the patient and control populations were in Hardy-Weinberg equilibrium (for patients: χ^2^=1.18; df=2 ; p=0.55 ;and for controls: χ^2^=0.03; df=2 ; p=0.98). As summarized in [Table 1](#T1){ref-type="table"}, no statistically significant difference was observed in genotypic distribution or allele frequencies between the total patients and controls (χ^2^=0.905, df=2, p=0.64 and χ^2^=0.001, df=1, p=0.97, respectively). Analysis by sex was avoided due to the unavailability of sufficient number of samples. However, [Table 1](#T1){ref-type="table"} shows that heterozygosity is higher in the male patients group (62.2%) than that in the control group (49%) (OR (95%) =1.7, CI (0.83-3.5), χ^2^=2.19, df=1, p=0.13).
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Discussion {#sec1-4}
==========

Few studies have reported a positive association between the COMT-L allele and schizophrenia\[[@ref5][@ref13]\]. Ohmari et al.\[[@ref5]\] showed that The COMT-L allele had a 1.47-fold increased risk for schizophrenia (95% CI=1.04--2.09; *P*=0.028). They also observed a significant difference in genotype distribution (*P*=0.026).The frequency of COMT-L allele was 27% in the healthy Japanese population, and 36% in the schizophrenics. The other study by Park et al.\[[@ref13]\] also showed a positive association. The COMT-L allele had a 1.7-fold increased risk for schizophrenia (95% CI=0.9--3.1), when they stratified schizophrenics by family history, they found a 4-fold increased risk for schizophrenia compared with controls. The frequency of the COMT-L allele was 19.90% in the healthy Korean population and 27.18% in the schizophrenics. On the contrary, other studies reported that the COMT-H allele may be associated with schizophrenia\[[@ref14][@ref15]\]. Wondoi et al.\[[@ref14]\] found that the frequency of the COMT-H allele was significantly higher in schizophrenia cases compared to controls (62.0% vs. 50.6%; *P*=0.043). A meta-analysis by Glatt et al.\[[@ref15]\] showed significant association between the COMT-H allele and schizophrenia in European populations (odds ratio=2.2, 95% CI=1.4--3.4, *P*=0.001).

To our knowledge, this is the first study to investigate the association between the Val158Met polymorphism of the *COMT* gene and schizophrenia in a Syrian population. This study failed to demonstrate any statistically significant genetic association between neither the COMT-L allele nor the COMT-H allele and schizophrenia. These negative results of our study are in agreement with several other studies and meta-analyses\[[@ref16]--[@ref22]\].

Although the results do not support the hypothesis that a link exists in this population, the higher heterozygosity in the male patients group than that in the control group suggests that heterozygosity is a susceptibility factor in males. This is in sharp contrast with a recent paper suggesting that heterozugosity has a protective effect against Schizophrenia based on the overdominance modal\[[@ref9]\]. One possible cause of our results is type 2 error, due to a relatively small sample size. Hence, replication in a larger sample, especially for males, may be warranted.

Conclusion {#sec1-5}
==========

We investigated the role of Val158Met polymorphism of the *COMT* gene in Schizophrenia susceptibility in an Arab population from Syria. The overall results indicate little effect of the studied polymorphism on the susceptibility for developing schizophrenia in the population studied.
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